Evidence map›Paper›PMID 41963640›Full record

ReviewBone marrow transplantation2026

Bringing the rare into sight: applications of haploidentical stem cell transplantation in the treatment of rare diseases.

Xiao-Di Ma, Zheng-Li Xu, Xiao-Jun Huang

Abstract readReview
PubMed Publisher
In one paragraph

Review in Bone marrow transplantation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Xiao-Di MaPeking University People's Hospital, Peking University Institute of Haematology, National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.
Zheng-Li XuPeking University People's Hospital, Peking University Institute of Haematology, National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China.ORCID 0000-0002-5018-6507
Xiao-Jun HuangPeking University People's Hospital, Peking University Institute of Haematology, National Clinical Research Center for Haematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China. xjhrm@medmail.com.cn.ORCID 0000-0002-2145-6643

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Haploidentical haematopoietic stem cell transplantation (haplo-HSCT) has transformed the management of haematological diseases by enabling the use of partially matched family donors, thereby markedly expanding donor availability. Advances in transplant platforms, including ex vivo TCRαβ

Indexed as

Hematopoietic Stem Cell TransplantationRare DiseasesTransplantation ConditioningTransplantation, HaploidenticalHumans

Identifiers

PMID41963640

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.